ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT APRIL 2025

Zinzino group revenue increased with a total of 54 %, compared with the previous year.

 

The revenue in April for Zinzino's sales markets increased by 58 % and amounted to SEK 249.5 (158.0) million. Faun Pharma's external sales decreased and amounted to SEK 6.2 (8.2) million. Overall, the Group increased revenues by 54 % to SEK 255.7 (166.2) million compared with the previous year.

Accumulated revenue for January – April 2025 increased by 58 % to SEK 979.4 (620.7) million.

Revenues were distributed as follows:

Regions,MSEK	25-Apr	24-Apr	Change	YTD 2025	YTD 2024	Change
The Nordics	23.5	25.0	-6%	100.7	93.0	8%
Central Europe	65.6	45.5	44%	262.0	165.0	59%
East Europe	27.2	31.1	-13%	124.4	124.9	0%
South & West Europe	45.0	26.4	70%	169.9	97.1	75%
The Baltics	8.7	8.2	6%	37.4	32.0	17%
North America	51.5	15.3	237%	164.0	50.7	223%
Asia-Pacific	26.3	5.4	387%	92.1	17.8	417%
Africa	1.7	1.1	55%	6.7	4.4	52%
Zinzino	249.5	158.0	58%	957.2	584.9	64%
Faun Pharma	6.2	8.2	-24%	22.2	35.8	-38%
Zinzino Group	255.7	166.2	54%	979.4	620.7	58%

 

Countries in regions:

-The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden

-Central Europe: Austria, Germany, Switzerland

-East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania

-South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland, Serbia, Turkey, Canary Islands

-The Baltics: Estonia, Latvia, Lithuania

-North America: Canada, USA, Mexico

-Asia-Pacific: Australia, New Zealand, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand

-Africa: South Africa

 

For more information:

Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, www.zinzino.com

 

Pictures for publication free of charge: marketing@zinzino.com

 

Certified Adviser: Carnegie Investment Bank AB (publ.)